Expressions of Ezrin and Pip5k1α Proteins in Airway Smooth Muscle of Asthmatic Patients
Recruiting · NCT06427018 · Observational (researchers observe without assigning treatment) · Lead sponsor: Lei-Miao Yin
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Asthma, a prevalent chronic respiratory affliction, significantly impinges upon the quality of life for affected individuals. Timely and appropriate diagnostic measures, coupled with efficacious therapeutic interventions, are paramount in mitigating exacerbations of symptoms and enhancing the life quality of patients. Ezrin plays an important role in maintaining cell morphology, cell migration, cell adhesion and polarisation, but Ezrin expression in airway smooth muscle remains unclear. Pip5k1α is an important kinase involved in intracellular phosphatidylinositol signalling pathways that may be involved in smooth muscle contraction and diastole. Therefore, further studies are necessary to elucidate the changes of Ezrin and Pip5k1α in patients with asthma to provide a basis for investigating alternative treatments for asthma.
Who can take part
Inclusion criteria
- Lung tissue samples;
- The samples come from patients aged 18-70 years old, regardless of gender, who underwent lung tissue sampling for surgical indications during treatment;
- Paraffin sections of lung tissue from patients diagnosed with bronchial asthma, including tracheal smooth muscle;
- Paraffin sections of lung tissue from non-asthma patients, including tracheal smooth muscle.
Exclusion criteria
- Paraffin sections of lung tissue from patients who have been diagnosed with COPD;
- Other situations where the researcher deems it inappropriate to participate in this study.
Where it is running
1 location listed.
- Yueyang Hospital, Shanghai University of Traditional Chinese Medicine - Shanghai, Shanghai Municipality, China